-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent news, Novartis announced that it has signed an agreement with Roche worth approximately US$20.
7 billion to sell 53.
3 million shares, or about 33% of Roche’s shares
.
This also means that Novartis and Roche's 20-year "marriage" finally broke up
.
In May 2001, Novartis began to acquire a 20% stake in Roche, which was expanded to 33% in 2003
.
Currently, it holds 53.
3 million free float shares of Roche, accounting for approximately 33% of Roche's total free float shares
.
This long-term investment has generated significant recurring income and accumulated dividends of more than US$6 billion for Novartis
.
During the holding period, the annualized rate of return in US dollars was 10.
2%, and the annualized rate of return in Swiss francs was 6.
6%
.
Although the returns are substantial, Novartis believes that its financial investment in Roche is neither its core business nor its strategic assets
.
Novartis will report the proceeds of the equity sale after the core adjustment, and the total proceeds are expected to be approximately US$14 billion
.
In fact, as early as May 2016, the then CEO of Novartis stated that Novartis might sell all Roche shares, worth about 13.
7 billion Swiss francs, without a premium, and would use the funds for company mergers and acquisitions.
.
However, in October of the same year, Swiss media reported that Novartis had terminated this plan
.
Now after five years, Novartis finally made the decision to sell Roche's equity
.
In recent years, Novartis has been spinning off the company's non-core businesses
.
For example, in 2018, Novartis sold a 36.
5% stake in a consumer healthcare joint venture to GSK for $13 billion; in April 2019, Novartis announced the spin-off of its eye care subsidiary Alcon, and shares in Switzerland and New York.
It is listed and traded on the stock exchange; in the three quarterly report released in October this year, Novartis also revealed that it is considering splitting or selling its generic drug business unit Sandoz
.
According to people familiar with the matter, Novartis senior management has discussed this plan, and the direction of the discussion is to promote the listing of the generic drug subsidiary Sandoz on the Swiss stock exchange.
.
According to the third quarter of 2021, the Novartis Group’s quarterly net sales were US$13.
03 billion, compared with US$12.
259 billion in the same period last year
.
The quarterly net profit was US$2.
758 billion, compared with US$1.
932 billion in the same period last year
.
Among them, the net sales of innovative drugs were US$10.
628 billion, a year-on-year increase of 6%
.
Sandoz (Sandoz) net sales of 2.
402 billion US dollars, a year-on-year increase of 1%
.
The industry has also expressed great concern about where Novartis has obtained funds after the sale
.
There is news that Novartis' handling of the funds may be a large-scale acquisition
.
Some people believe that Alnylam Pharmaceuticals will be Novartis' main potential acquisition target
.
This is the developer of RNA interference (RNAi) technology behind the newly acquired cholesterol drug Leqvio, which Novartis spent $3.
3 billion.
The drug is expected to be approved by the US FDA soon
.
Novartis and Alnylam have been cooperating for some time.
Before the acquisition of Leqvio developer The Medicines Company, Novartis announced a partnership with Alnylam in 2005
.
However, in 2014, Novartis slowed down the cooperation for a number of reasons, including mentioning formulation and delivery challenges, and the limited range of relevant targets that can be used with siRNA
.
Alnylam is currently in a transitional period for the CEO, and investors see this transition as reducing the possibility of the company's choice of mergers and acquisitions within six months in the near future
.
In addition, gene therapy company BioMarin Pharmaceutical may also be a potential acquisition target for Novartis.
Industry analysts have also suggested that companies such as cell and gene therapy developer Sangamo Therapeutics and CGRP migraine drug developer Biohaven may be targets for Novartis' acquisition
.
7 billion to sell 53.
3 million shares, or about 33% of Roche’s shares
.
This also means that Novartis and Roche's 20-year "marriage" finally broke up
.
In May 2001, Novartis began to acquire a 20% stake in Roche, which was expanded to 33% in 2003
.
Currently, it holds 53.
3 million free float shares of Roche, accounting for approximately 33% of Roche's total free float shares
.
This long-term investment has generated significant recurring income and accumulated dividends of more than US$6 billion for Novartis
.
During the holding period, the annualized rate of return in US dollars was 10.
2%, and the annualized rate of return in Swiss francs was 6.
6%
.
Although the returns are substantial, Novartis believes that its financial investment in Roche is neither its core business nor its strategic assets
.
Novartis will report the proceeds of the equity sale after the core adjustment, and the total proceeds are expected to be approximately US$14 billion
.
In fact, as early as May 2016, the then CEO of Novartis stated that Novartis might sell all Roche shares, worth about 13.
7 billion Swiss francs, without a premium, and would use the funds for company mergers and acquisitions.
.
However, in October of the same year, Swiss media reported that Novartis had terminated this plan
.
Now after five years, Novartis finally made the decision to sell Roche's equity
.
In recent years, Novartis has been spinning off the company's non-core businesses
.
For example, in 2018, Novartis sold a 36.
5% stake in a consumer healthcare joint venture to GSK for $13 billion; in April 2019, Novartis announced the spin-off of its eye care subsidiary Alcon, and shares in Switzerland and New York.
It is listed and traded on the stock exchange; in the three quarterly report released in October this year, Novartis also revealed that it is considering splitting or selling its generic drug business unit Sandoz
.
According to people familiar with the matter, Novartis senior management has discussed this plan, and the direction of the discussion is to promote the listing of the generic drug subsidiary Sandoz on the Swiss stock exchange.
.
According to the third quarter of 2021, the Novartis Group’s quarterly net sales were US$13.
03 billion, compared with US$12.
259 billion in the same period last year
.
The quarterly net profit was US$2.
758 billion, compared with US$1.
932 billion in the same period last year
.
Among them, the net sales of innovative drugs were US$10.
628 billion, a year-on-year increase of 6%
.
Sandoz (Sandoz) net sales of 2.
402 billion US dollars, a year-on-year increase of 1%
.
The industry has also expressed great concern about where Novartis has obtained funds after the sale
.
There is news that Novartis' handling of the funds may be a large-scale acquisition
.
Some people believe that Alnylam Pharmaceuticals will be Novartis' main potential acquisition target
.
This is the developer of RNA interference (RNAi) technology behind the newly acquired cholesterol drug Leqvio, which Novartis spent $3.
3 billion.
The drug is expected to be approved by the US FDA soon
.
Novartis and Alnylam have been cooperating for some time.
Before the acquisition of Leqvio developer The Medicines Company, Novartis announced a partnership with Alnylam in 2005
.
However, in 2014, Novartis slowed down the cooperation for a number of reasons, including mentioning formulation and delivery challenges, and the limited range of relevant targets that can be used with siRNA
.
Alnylam is currently in a transitional period for the CEO, and investors see this transition as reducing the possibility of the company's choice of mergers and acquisitions within six months in the near future
.
In addition, gene therapy company BioMarin Pharmaceutical may also be a potential acquisition target for Novartis.
Industry analysts have also suggested that companies such as cell and gene therapy developer Sangamo Therapeutics and CGRP migraine drug developer Biohaven may be targets for Novartis' acquisition
.
